Australian Dementia Forum 2021 1 Australian Dementia Forum 2021 31 May – 1 June Virtual Handbook www.adf2021.org.au [email protected] The Australian Dementia Network Dementia is a major and growing health issue for Australians. In 2020, an estimated 459,000 people are living with dementia and this number is growing by about 250 persons each day. Dementia is the second leading cause of death of Australians and is the single greatest cause of disability in Australians aged 65 and over. It is estimated to cost the nation more than $15 billion annually. The Australian Dementia Network (ADNeT) brings together Australia’s leading scientists, researchers, and clinicians into the largest national network of experts in Alzheimer’s disease and other forms of dementia. Through our research, we strive to improve the quality of clinical care for people with dementia and mild cognitive impairment Use the conference social and accelerate the development of new therapies. Our initiatives media handles to share Our work is organised around three key initiatives that interact to deliver value and tangible benefits for people living with dementia and their care partners. your comments, feedback, The Australian Dementia Network The Australian Dementia The Australian Dementia Network Screening and Trials Program – Network Registry – A Clinical Memory Clinic Initiative - Cutting-edge specialist Quality Registry to drive harmonising the diagnostic diagnostics continuous quality standards of memory clinics experience of the improvement in clinical care The Australian Dementia Network The Australia Dementia Network Screening and Trials initiative is The Australian Dementia Network Memory Clinics initiative is working to creating opportunities for Australians Registry is a clinical quality registry harmonise the diagnostic standards of conference. living with dementia to access new for people newly diagnosed with memory clinics across Australia and therapies under development by either dementia or mild cognitive develop training, professional facilitating recruitment into clinical trials impairment. It collects data about development, and easily accessible https://twitter.com/ADF2021 https://www.facebook.com/ADF2021/ across Australia. It provides clinicians the diagnosis, clinical care and clinical resources for health with cutting-edge specialist diagnostic outcomes of this population. professional staff. techniques for eligible patients free of For more information: For more information: cost. If your organisation is interested in To list your clinic on our national list, For more information: participating in the Registry or you available online, please email To refer your patient to our program, would like more information, contact [email protected] contact [email protected] or Bi-monthly webinars - Watch past [email protected] 1800 314 421. webinars on our YouTube channel or Interested individuals can register to register via our website or our social participate in clinical trials – see media channels. https://www.australiandementianetw Or contact us at ork.org.au/i-am-a-member-of-the-pub [email protected] for more lic-or-consumer/volunteer-for-trials/ information. For more information, contact Dr Jo Robertson, our national ADNeT Screening and Trials coordinator, on [email protected] or 0408 508 121. Stay in touch www.australiandementianetwork.org.au @ADNeT_Australia Australian Dementia Network Faculty of Medicine, Dentistry and Health Sciences [email protected] Level 2, Alan Gilbert Building +61 3 9035 9635 The University of Melbourne Victoria 3010 Australia LISTEN TO WHAT THE FUTURE HAS TO SAY IN Join the new conversation with leaders, influencers, innovators and brilliant minds about the future of Alzheimer’s disease. For Australian Healthcare Professionals. ®Biogen is a registered trademark of Biogen MA Inc. Biogen Australia, Macquarie Park NSW. ©2021. Biogen-105259. BGAD21440W. Date of preparation: April 2021. 4 www.adf2021.org.au Australian Dementia Forum 2021 5 Sponsors Platinum Sponsor Gold Sponsor About NHMRC About Biogen NHMRC has been supporting health and medical research and advancing health At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen and medical knowledge to improve the health of all Australians since 1937. discovers, develops, and delivers worldwide innovative therapies for people NHMRC’s mission is building a healthy Australia. living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology As the Australian Government’s lead agency for funding health and medical companies, Biogen was founded in 1978 by Charles Weissmann, Heinz research, NHMRC invests in the creation of knowledge about the mechanisms Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip underlying health and disease and in the development of better ways to prevent Sharp. Today Biogen has the leading portfolio of medicines to treat multiple and treat ill health. We support the translation of evidence from research into sclerosis, has introduced the first approved treatment for spinal muscular public health policy and clinical practice, and we promote the highest standards atrophy, commercializes biosimilars of advanced biologics, and is focused of research ethics and integrity. on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement We fund research across the spectrum from discovery to implementation disorders, ophthalmology, neuropsychiatry, immunology, acute neurology, and science. We balance the needs of the community, government and the research neuropathic pain. sector, supporting both investigator-initiated and priority-driven research. We understand the important contribution that health and medical research makes For more information, please visit www.biogen.com.au or www.biogen.co.nz to creating knowledge and improving lives. NHMRC is proud to support the 2021 Australian Dementia Forum (ADF 2021). The NHMRC National Institute for Dementia Research (NNIDR), delivered in partnership with Dementia Australia, closed on 30 June 2020 after a successful Gold Sponsor five years supporting the Australian dementia research sector and assisting with the delivery of the Australian Government’s Boosting Dementia Research Initiative (BDRI). About CSIRO NHMRC remains committed to supporting dementia research. For more CSIRO, Australia’s national science agency, is committed to solving the nation’s information, please visit the NHMRC dementia research webpage. greatest health challenges through innovative science and technology. The Australian e-Health Research Centre (AEHRC) is CSIRO’s digital health research program – enabling the digital transformation of healthcare to improve services and clinical treatment for Australians. The AEHRC works with collaborators across the healthcare system to improve diagnosis and treatment. In aged care, the AEHRC brings our expertise in biomedical imaging and genomics, to enable early precision healthcare in diagnosis and treatment, while our health service research develops technologies that support services for those living with dementia. For more information, please visit https://aehrc.com/ 6 www.adf2021.org.au Australian Dementia Forum 2021 7 Contents Virtual Sponsor About Actinogen Convenors Welcome ..............................................8 Actinogen Medical is developing novel therapies for neurological diseases associated with dysregulated Organising Committee .......................................... 10 brain cortisol. We are currently developing the lead compound, Xanamem™, as a promising new therapy for Alzheimer’s disease, Fragile X syndrome, and other neurological diseases. Xanamem’s novel mechanism Keynote Speakers ....................................................11 of action works by blocking the production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. Actinogen is planning to commence multiple phase II trials Virtual Platform information .............................. 14 targeting improved cognition and other potential benefits. Attendee Participation ..........................................17 For more information visit www.actinogen.com.au Technical Support ....................................................17 Program ..................................................................... 19 Frequently Asked Questions ...............................20 Supporting Partners 8 www.adf2021.org.au Australian Dementia Forum 2021 9 Convenor Welcome Dear delegates, y The Hon Greg Hunt MP, Minister for Health, Due to COVID, travel bans, regular outbreaks and the for accepting our invitation to officially need to keep presenters and participants safe, we Welcome to the Australian Dementia Forum 2021. open the conference. chose to run ADF2021 as a fully virtual conference. While many of us prefer the experience of face-to- y presenters and keynote speakers, face participation, we do hope that you will enjoy It is just 2 weeks short of 2 years since the previous especially those who graciously accepted the conference and the many participation and Australian Dementia Forum was held in Tasmania, but to participate in live Q&A sessions despite networking opportunities that it offers. so much has changed in that time. time zone differences and some very early/late starts. COVID